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ABSTRACT 
 Individuals with fragile X syndrome (FXS) experience disproportionate rates of 
diagnoses of attention-deficit/hyperactivity disorder (ADHD) when compared to the 
general population. Exact prevalence rates and outcomes for individuals with a diagnosis 
of FXS and ADHD is not well known.   The current study assesses rates of ADHD 
diagnosis in individuals with FXS as well as tests the prediction of a diagnosis of ADHD 
from levels of autism spectrum disorder (ASD) symptom presentation. The present study 
included 30 individuals with FXS aged 13-25 and were assessed using a structured 
diagnostic interview. Interviews were conducted with individual’s parents’ due to low 
cognitive ability found in individuals with FXS. ASD symptoms were not found to be a 
significant predictor of ADHD in our sample. Diagnostic prevalence rates of ADHD were 
found to be 45% for the FXS sample. Individuals with FXS experience diagnostic rates of 
ADHD significantly higher than those found in the general population. The presence of 
ASD does not appear to account for the differences found in these rates.
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 ATTENTION DEFICIT/HYPERACTIVITY DISORDER  
       Attention Deficit/Hyperactivity Disorder (ADHD), is a neurodevelopmental 
disorder marked by symptoms of hyperactivity, inattention, and executive functioning 
deficits (Akinbami, Liu, Pastor, & Reuben, 1998; Nikolas, Klump, & Burt, 2015). It is 
the most commonly diagnosed behavioral disorder in typically developing children with 
rates of ADHD in the general population ranging from 9-11% during childhood to about 
4% in adults (APA, 2013; Kessler et al., 2006). The DSM 5th Edition (DSM-5) breaks 
ADHD into two subgroups: inattentive (ADHD-I) and hyperactive/impulsive (ADHD-H; 
APA, 2013). Additionally, a diagnosis of ADHD combined (ADHD-C) type can be 
received when diagnostic criteria is met for both inattentive and hyperactive types. In 
children with ADHD, symptoms present through a spectrum of deficits that can impact 
academic, social and cognitive functioning (De Boo & Prins, 2007; Solanto, Pope-Boyd, 
Tryon, & Stepak, 2009). 
 Children with a diagnosis of ADHD are prone to a number of negative 
developmental risk factors that can have cascading impacts on their functioning. For 
example, children with ADHD are often more socially rejected by their peers and are also 
viewed more negatively by their peers (De Boo & Prins, 2007). In many cases, this is due 
to the fact that children with ADHD have difficulty staying on topic in conversations, 
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often initiate or engage in conversations at inappropriate times, and engage in frequent 
off-task and rule breaking behaviors (De Boo & Prins, 2007; Erhardt & Hinshaw, 1994). 
Cumulatively, these behaviors in childhood lead to maladaptive social functioning in 
adults who continue to experience symptoms and consequences of ADHD later in life. In 
fact, adults with ADHD are more likely to be incarcerated, engage in drug use, be 
unemployed, miss more days of work and have less education than adults without ADHD 
(Secnik, Swensen, & Lage, 2005). In addition, adults with ADHD are found to change 
occupations more frequently, and have a higher number of failed relationships (Barkley, 
Fischer, & Smallish, 2002; Biederman, 2004).  
 As can be seen, the impacts of ADHD in the general population can have 
severe consequences. In addition to the general population, the symptoms of ADHD have 
been found to be pervasive and impairing in specific neurodevelopmental disorders 
including fragile X syndrome (FXS) and non-syndromic autism spectrum disorder 
(ASD). Studying the presentation of ADHD in high risk neurodevelopmental groups such 
as FXS and ASD is important because of the significant impact that a comorbid diagnosis 
of ADHD can have on the functioning and long-term outcomes for persons with these 
disorders. Additionally, studying ADHD in the presence of two disorders that also have 
elevated features of ASD will advance the field to a greater understanding of the unique 
and shared dimensions of the behavioral phenotypes found in non-syndromic ASD and 
autism associated with FXS. As such, studying ADHD in these high risk 
neurodevelopmental groups is ideal for furthering our understanding of the underpinnings 
and phenotypic expression of ASD, FXS and ADHD independently and collectively.  
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1.2 FRAGILE X SYNDROME  
Fragile X syndrome is a monogenetic disorder that is the primary known genetic 
cause of ASD and intellectual disability (ID; Scerif, et al., 2012). The full mutation is 
identified by a cytosine-guanine-guanine (CGG) repeat >200 on the FMR1 gene found on 
the X chromosome. The CGG repeat expansion is associated with reduced fragile X 
mental retardation protein (FMRP), which is involved in typical brain maturation. Fragile 
X syndrome affects 1: 5,000 live births in males (Centers for Disease Control, 2015). The 
behavioral phenotype of FXS is marked by high levels of challenging behaviors and 
symptoms such as inattention, hyperactivity, and hyperarousal; these symptoms are all 
related to ADHD (Hatton et al., 2002; Thurman, McDuffie, Hagerman, & Abbeduto, 
2014).  
FXS is associated with a number of comorbidities, however, ADHD has been 
found to be the most common and diagnosable condition in individuals with FXS 
(Backes et al., 2000; Baumgardner, Reiss, Freund, & Abrams, 1995). Even though 
ADHD is the most commonly diagnosed behavioral disorder in FXS, reported rates of 
ADHD in individuals with FXS vary depending on age and type of measure utilized 
(Sullivan, 2006). Per some reports, approximately 22% to 74% of males with FXS 
display features of at least one of the three sub-types of ADHD (Backes, Genc, Schreck, 
et al., 2000; Lo-Castro, D’Agati, & Curatolo, 2011; Reilly, Senior, & Murtagh, 2015). 
Hyperactivity and inattention are hallmark behavioral features of both ADHD and FXS; 
however, direct investigation of overlaps in these symptom profiles and diagnostic rates 
in the presence of FXS has only been investigated to a limited degree (Reilly, Senior, & 
Murtagh, 2015). This points to the need of identifying which of these behavioral features 
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results from either FXS or ADHD. Further, this information will allow for the 
understanding of the behavioral underpinnings of ADHD symptom presentations to aid in 
the development of targeted treatments and interventions within each of these individual 
clinical groups. 
Multiple studies have investigated symptom prevalence rates in children and 
adolescents with FXS using symptom based behavioral measurement. (Backes et al., 
2000; Bailey, Raspa, Olmsted, & Holiday, 2008; Hartley et al., 2011; Newman, Leader, 
Chen, & Mannion, 2015; Smith, Barker, Seltzer, Abbeduto, & Greenberg, 2012; Sullivan 
et al., 2006). Most often behavioral rating scales are filled out by parents, rating their 
child’s behavior. Symptom based behavioral measures are continuous in their 
measurement system and allow for researchers to examine features of a disorder and 
change in behavior over time, independent of whether the symptoms are sufficient to 
warrant a formal diagnosis. Across studies utilizing rating scales to examine ADHD in 
FXS, symptom rates (either meeting borderline or clinically significant rates) varied 
greatly depending on composition of sample and types of measures used with symptom 
rates ranging from 36% to 78% (Lachiewicz, 1992; Lachiewicz and Dawson, 1994; 
Baumgardner et al., 1995; Backes et al., 2000; Hatton et al., 2002, as cited in Sullivan et 
al., 2006). Specifically, the highest rates of symptom presentation appear evident when 
the Child Behavior Checklist (CBCL) Attention Scale is utilized with 78% to 80% 
scoring above clinical significance on this scale across multiple samples  (Bailey et al., 
2008; Newman et al., 2015).  
In contrast, relatively few studies have examined diagnostic prevalence rates of 
ADHD in children with FXS utilizing a diagnostic measure as opposed to symptom based 
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measures (Backes et al., 2000; Sullivan et al., 2006). In the diagnostic based literature, 
rates of ADHD in males with FXS are reported to range from 54% to 74% (Backes et al., 
2000; Sullivan et al., 2006) which is significantly higher than the rates of both ~10% for 
children and 4% for adults in the general population.  The diagnostic rates for ADHD in 
FXS are somewhat lower than symptom-based rates as they fall in the lower end of what 
has been found in the symptom based literature. This is to be expected when using 
screening measures that are aimed at over identifying individuals for a range of different 
disorders to allow for more careful, targeted examination of an individual’s behavior. 
When examining the methodology of both symptom and diagnostic based studies more 
closely, there is a lack of utilization of ADHD specifc measures (i.e. Conner’s-3). 
Utilizing ADHD specific measures in individuals with FXS may give a clearer and more 
accurate picture of what true comorbid rates of ADHD are.   
Further concerns related to the lack of ADHD specific diagnostic literature for 
individuals with FXS relates to the ability to interpret the findings from the literature that 
does exist. Of the two diagnostic studies found in the literature, each only used a sample 
of children and adolescents, and do not extend into the adult population. Additionally, the 
genetic composition of the samples in these studies not being homogeneous; with one 
including both males and females with the full mutation in their sample (Sullivan et al., 
2006) and the other including males with the full and pre-mutation (Backes et al., 2000). 
Backes (2000) also excluded individuals who could not understand the instructions of the 
cognitive assessment thus possibly introducing a skew with more cognitively capable 
individuals being included in their sample. This is not standard practice in studies 
indcluding individuals with FXS given intellectual disability (ID) is a hallmark feature of 
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FXS. This wide prevalence range and lack of structure in the genetic makeup of previous 
samples calls for the need for more research to help us understand in what symptom 
domains and at what ages the impact of ADHD is on individuals with FXS.  
Given what we know about the impacts of the symptoms of ADHD in the general 
population and the poor life course trajectory for individuals with FXS, outcomes for 
adults with FXS who also have a comorbid diagnosis of ADHD are expectedly poor 
(Hartley et al., 2011). In a longitudinal study aimed at looking at the impact of ADHD in 
childhood on social functioning in adults with FXS,  found that elevated ADHD 
symptoms were a significant predictor of impaired social functioning for males with FXS 
15-25 years old (Chromik et al., 2015). Thus, the impacts of ADHD symptomatology in 
FXS early in life has significant implications for life course trajectory and independence 
later in life for these individuals. However, in a national, one-time, survey study of 
functioning in adults with FXS, did not find inattention and hyperactivity to be directly 
related to poor outcomes in adulthood (Hartley et al., 2011). However, regardless of other 
diagnoses or conditions, inattention and hyperactivity have been shown to significantly 
impact an individual’s ability to build friendships and engage in appropriate social 
interactions. In the same study, the two strongest predictors of positive adult outcomes 
for individuals with FXS were functional skills and appropriate social interactions 
(Hartley et al., 2011). Thus, the well-documented negative impacts that ADHD has on 
social skills is a likely contributor to impairments for individuals with FXS across early 
childhood with important implications for functioning later in life.  
In summary, ADHD is highly prevalent and significantly impairing in individuals 
with FXS.  However, significant limitations are present across many studies, yielding 
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caution when interpreting their results. Three of the primary limitations include failure to 
control for large variability in the age and genetic status in samples, a lack of study in the 
adolescent and young adult developmental stage, and an over-reliance on rating scales 
rather than diagnostic measures.  As such, the present study will contribute to the 
literature by targeting a genetically homogenous sample of adolescents and adults with 
FXS and using a diagnostic interview. 
1.3 AUTISM SPECTRUM DISORDER 
Autism spectrum disorder (ASD) is a social communication and restricted and 
repetitive behavior disorder that affects 1: 68 children (CDC, 2015). ASD is a highly 
heritable disorder, with a largely heterogeneous etiology. Research shows that 22% to 
83% of children with ASD are also diagnosed with ADHD (see review by Leitner, 2014). 
Prior to the most current version of the DSM, ADHD could not be diagnosed in the 
presence of ASD. However, now that these two disorders may be co-diagnosed, the need 
to study and understand each of them in isolation, as well as in the presence of one 
another, is imperative. Consistent with the literature on FXS and ADHD, the type of 
sample, age of participants, and types of measures used are important factors that 
contribute to the variance in reported prevalence rates for individuals with non-syndromic 
ASD (Visser, Rommelse, Greven, & Buitelaar, 2016). 
Many of the negative social implications of ASD are also experienced by children 
who receive a diagnosis of ADHD demonstrating significant symptom overlap. Peer 
rejection and difficulty entering and maintaining appropriate conversations impact 
children with ASD and those with ADHD without ASD (Ashwood et al., 2015). Further, 
a review aimed at summarizing what the field currently knows about the comorbidity of 
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ASD and ADHD points to a number of studies find that children with comorbid ASD and 
ADHD have lower cognitive ability, lower adaptive skills, and greater impairments in 
social, emotional and school functioning (Leitner, 2014). Thus, the deficits presented by 
ASD alone, coupled with additional deficits created by ADHD, place children with these 
co-diagnoses at risk for poorer outcomes across multiple domains throughout their 
lifetime (Sikora, Vora, Coury, & Rosenberg, 2012). However, because little research has 
focused on the impacts of comorbid ASD and ADHD in adolescence or adulthood, little 
is known about how these co-diagnoses affect individuals later in life. Likewise, little 
research has been conducted on the presence and impact of individuals with non-
syndromic ASD who also have ID and ADHD. In one of the few existing studies, 17% of 
six to 17-year-old children with ASD+ID had ADHD (Stevens et al., 2016). The present 
study will expand upon this work by investigating rates of ADHD in a sample of 
adolescents and adults with non-syndromic ASD and comorbid ID contrasted to FXS. 
Within the context of FXS, about 60% of children with a diagnosis of FXS also 
receive a diagnosis of ASD (Harris et al., 2008). Previous research has shown that the 
presence of ASD does not consistently predict ADHD behaviors in individuals with FXS 
(Newman et al., 2015; Sullivan et al., 2006). The relationship of ASD severity and 
ADHD in FXS remains unclear, with some reports showing a relationship with autism 
severity features (Sullivan, 2006) and others not showing a relationship when autism is 
used as a grouping variable (Newman, 2015; Hatton, 2002). The present study aims to 
investigate the relationship of non-syndromic ASD (i.e., ASD without FXS or another 
genetic disorder) and ADHD symptoms in the presence of FXS. 
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1.4 SUMMARY 
 Rates of ADHD within individuals with FXS ranges from 40% to 80%. Rates of 
ADHD in individuals with ASD ranges from 14% to 78%. However, these rates are based 
upon a majority of samples comprised of children. Thus, little is known about the 
diagnostic rates of ADHD in FXS and ASD in a genetically and sex homogenous sample. 
Previous literature has shown that presence ADHD in either ASD or FXS is associated 
with overall greater impairment in functioning. Thus, the need to understand rates of 
ADHD in clinical adult populations is imperative to understand gaps in treatment and 
developmental trajectories of these comorbid disorders. 
1.5 THE CURRENT STUDY 
Presently, more is known about the genetics of FXS than about the behavioral 
phenotype (Tranfaglia, 2010). Despite the high prevalence and impairment associated 
with ADHD in specific neurodevelopmental disorders, little research has been conducted 
comparing adolescents and adults with non-syndromic ASD to FXS when looking at 
ADHD. In addition, no study has ever compared FXS to non-syndromic ASD with the 
goal of identifying ADHD within each of these high-risk populations with an older 
adolescent and adult sample. 
The present study aims to characterize the prevalence and predictors of ADHD 
using a DSM-based diagnostic interview employing a strict diagnostic criteria model 
requiring the presence of impairment complemented by consideration of the presence of 
features independent of impairment. The focus of this study is on adolescent and adult 
males with FXS contrasted to males with non-syndromic ASD given the high prevalence 
of ADHD in each of these populations. By taking a differential diagnostic approach to 
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known genetic and behaviorally similar neurodevelopmental disorders, we will contribute 
information to the field regarding diagnostic rates across these two disorders which will 
allow for more targeted interventions. 
1.6 RESEARCH QUESTIONS 
The following three primary research questions were addressed in this study, and 
the relevant hypotheses are included.   
1. What is the diagnostic prevalence of the three sub-types of ADHD 
(Inattentive, Hyperactive, and Combined) in an adolescent and young adult 
sample of males with FXS? It is hypothesized that 75% of our FXS sample 
will meet for a diagnosis of ADHD, with more individuals meeting for ADHD 
inattentive type, over the other two subtypes. 
2. Is autism symptom severity associated with a diagnosis of ADHD in 
adolescent and adult males with FXS? We hypothesize that higher levels of 
ASD symptomology will be found in individuals with FXS who also meet for 
a diagnosis of ADHD.  
3. Is the diagnostic prevalence of the three sub-types of ADHD (Inattentive, 
Hyperactive, Combined) different in adolescent and young adult males with 
FXS contrasted to males with non-syndromic ASD? It is hypothesized that 
overall ADHD diagnostic rates will be higher in the FXS sample than in the 
non-syndromic ASD sample. Further, it is hypothesized that all the ADHD 
diagnostic subtypes will be found to have higher rates in the FXS sample than 
in the non-syndromic ASD sample. 
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CHAPTER 2 
METHODS 
 
2.1 PARTICIPANTS 
Participants with FXS were drawn from a larger longitudinal, multiple site study 
focused on language development during the transition into adulthood (R01 PI: 
Abbeduto). Only individuals who participated at the University of South Carolina (USC) 
site were included in this study given a more focused interest on ADHD and the presence 
of sufficient resources at the USC site. The FXS group was recruited nationally through 
parent listservs, social media, postings by the National Fragile X Foundation, and with 
the help of the Research Participant Registry Core of the Carolina Institute for 
Developmental Disabilities at the University of North Carolina at Chapel Hill. 
Participants with non-syndromic ASD were recruited locally to each research site through 
local advertisements, social media, parent support groups, the South Carolina Department 
of Disabilities and Special Needs (n = 13) and participation in a complementary study (n 
= 7) at USC aimed at examining social communication profiles within families of 
children with ASD (F32 PI: Klusek). 
Participants included 31 males with FXS and 20 males with ASD. Ages ranged 
from 16-24 years old for the FXS group (M = 18.73, SD = 2.13) and 13-22 years old for 
the ASD group (M = 18.86, SD = 2.18). Average participant characteristics can be found 
for each group in Tables 2.1 and 2.2. Participants with FXS had the full mutation of the 
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FMR1 gene (> 200 CGG repeats) confirmed through genetic testing. Clinical diagnoses 
of autism within the non-syndromic ASD group were confirmed through study 
participation and the presence of FXS was ruled out based on a review of genetic records.  
All participants were verbally communicative (minimum combination of at least 
three words), spoke English as their primary language, and lived with their biological 
parents at least during the first year of enrollment in the study.  
2.2 PROCEDURES 
Data collection occurred based on established procedures of the larger language 
R01, which was designed with four annual assessments (Times 1-4), and the F32 which 
represented a single assessment. The current study focused on ADHD as an extension of 
both the larger R01 and F32 studies; thus, we accessed existing data that were part of 
each ongoing study along with the newly added ADHD diagnostic measure integrated 
into the existing protocols.  Per the standard protocol for the R01, the ADOS and 
cognitive scores were completed at Time 1 and the ADHD diagnostic measure was added 
in Year 2 (T2).  Study visits lasted two-days, and included a team of trained staff 
members who administered all behavioral assessments, and completed interviews with 
the participants’ mothers.  
2.3 MEASURES 
 2.3.1 ADHD DIAGNOSIS The Children’s Interview for Psychiatric Syndromes – 
Parent version (PChIPS; (Fristad, Teare, Weller, Weller, & Salmon, 1998), was 
administered to determine the presence of ADHD symptoms and diagnosis in the non-
syndromic ASD and FXS samples. The PChIPS is a structured parent interview used to 
assess presence of psychiatric disorders in children and adolescents aged 6-17 years old. 
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Table 2.1  
ASD Participant Characteristics  
 Whole Group 
n  20 
Age 17 years 6 months 
(23.28 months) 
Leiter Growth Score  489.85 (19.00) 
ADOS Severity 
Score 
7.2 (1.86) 
Race 
  African American 
  Asian 
  American Indian or       
  Alaskan Native 
  Hispanic Latino 
  Caucasian 
  Bi-racial 
 
10% 
5% 
0% 
5% 
75% 
5% 
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Table 2.2 
FXS Participant Characteristics 
 Whole Group With ASD Without ASD 
n  31  23 8 
Age 17 years 6 months 
(34.87 months) 
17 years 4 months 
(35.14 months) 
17 years 9 months 
(33.83 months) 
Leiter Growth 
Score  
459.9 (14.04) 456 (15.33) 466.5 (5.41) 
ADOS Severity 
Score 
5.677 (2.28) 5 (1.30) 2.375 (0.70) 
Race/Ethnicity African American 
9.6% 
Asian 3.2% 
American Indian or 
Alaskan Native 
3.2% 
Hispanic Latino 
6.4% 
Caucasian 77.4% 
African American 
0% 
Asian 0% 
American Indian or 
Alaskan Native 0% 
Hispanic Latino 
12.5% 
Caucasian 87.5% 
African American 
13% 
Asian 4.3% 
American Indian or 
Alaskan Native 
4.3% 
Hispanic Latino 
4.3% 
Caucasian 73.9% 
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It uses a DSM based diagnostic model to assess symptom count, duration, and 
impairment consistent with DSM criteria. Questions pertaining to symptomology are 
presented and scored in a yes/no format. The full version of the PChIPS assesses for 20 
DSM-IV disorders; however, only 10 of these disorders were administered to parents’ 
due to the nature of the behavioral phenotype of FXS and ASD. Only the ADHD section 
was included in analyses for the present study. The current version of the PChIPS 
assesses diagnostic criteria per the DSM-IV, however we considered the two major 
changes that DSM-5 made to the diagnostic criteria for ADHD. These are allowing the 
concurrent diagnosis of ADHD and ASD and for a retrospective ADHD diagnosis to be 
made if 5 symptoms were endorsed to be present before age 12. Since no changes were 
made to the symptoms listed for ADHD from DSM-IV to DSM-5, no structural changes 
were made to the PChIPS scoring form. Although all the participants in this study were 
above the age of 12, the number of symptoms needed to meet for a diagnosis of ADHD 
was still held at six, due to the average developmental age of individuals with FXS and 
those with low IQ. However, we also calculated the rates using the adult criteria of five 
symptoms to complement the child rates given no established procedure for applying 
DSM ADHD criteria to adolescent and adult samples with low mental ages (see Figure 
2.1 and 2.2). 
The PChIPS was first examined on a sample of 36 typically developing children 
aged six to 13 years of age (Fristad, et al, 1998). Of the 36 participants included in the 
study, 78% were boys. The study aimed at determining the convergent validity of the 
PChIPS with the original interview, the Children’s Interview for Psychiatric Syndromes 
(Weller, Weller, Fristad, Rooney, & Schecter, 2000). For ADHD, a kappa coefficient of 
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0.122 was found between the ChIPS and the PChIPS, with 50% agreement between the 
two measures. (Fristad, et. Al, 1998).  
The PChIPS has also been investigated with a sample of ASD children using the 
Child and Adolescent Symptom Inventory (CASI; Witwer, 2012), where strong intraclass 
correlation coefficients (ICC’s) were found (Hyperactive = .92, Inattentive = .97, and 
Combined = .93) but fair to moderate kappa agreements (Hyperactive = 0.43, Inattentive 
= 0.60, and Combined = 0.27). Although the PChIPS has not yet been used in a FXS 
sample, it was designed for individuals with the same mental age as the participants 
included in this study. Inter-rater reliability was calculated based upon percent agreement 
for type of ADHD sub-type diagnosis. Twenty percent of the FXS sample had reliability 
calculated ad 25% of the ASD group had reliability calculated. Percent agreement was 
100% for both groups. The categorical distinction of presence/absence of an ADHD 
disorder based on DSM-5 criteria was the primary dependent variable in the analyses.   
2.3.2 ASD SYMPTOM SEVERITY The Autism Diagnostic Observation Schedule-
Second Edition (ADOS-2; Lord et al., 2012) was administered to confirm autism 
diagnostic status in the ASD group, determine ASD status in the FXS group, and 
document severity of ASD features across groups. The ADOS-2 consists of a series of 
semi-structured interviews and play opportunities between an examiner and a participant, 
allowing for the observation of developmentally appropriate and inappropriate responses 
to these social exchanges. The ADOS-2 also used a continuous index of ASD symptoms 
by utilizing severity scores for overall behaviors. These overall symptom severity scores 
were used in analysis as a predictor for ADHD in the FXS group. The ADOS-2 was 
administered and scored live by graduate-level professionals who completed standard 
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Figure 2.1. Bar graph showing inattentive symptom level endorsement. 
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Figure 2.2 Bar graph showing hyperactive/impulsive symptom level endorsement. 
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research reliability training. Ten percent of the administrations were randomly selected 
and second-scored by video for inter-reliability across both groups which was yielded to 
be above 80% across all items and algorithm scoring for the ADOS-2. The severity score 
was used as a continuous variable indicating degree of ASD symptom severity.   
2.3.3 COGNITIVE ABILITY The Leiter-R is a non-verbal intelligence measure 
intended for use in subjects who have limited receptive and expressive language 
capabilities. Growth scores obtained from the Leiter-R were used in analysis to control 
for floor effects. Due to low cognitive abilities in these populations floor effects can 
significantly affect standard scores, thus impacting analyses (Roid & Miller, 1997).  The 
growth score was used as a continuous variable to indicate cognitive level.  
2.4 STATISTICAL ANALYSES  
Data were analyzed using IBM SPSS Statistics 24. To examine our first and third 
research questions, diagnostic prevalence rates for each of the two groups were 
determined by calculating proportion of participants that met criteria for a DSM-5 
diagnosis of ADHD. Proportions were also calculated based on symptom count criteria 
for each of three sub-types of ADHD. To answer our second research, question a logistic 
regression model was built including autism symptom severity as a predictor of ADHD 
diagnosis. Correlations were run to determine appropriateness of predictors included in 
the model. To answer our third research question, chi-squared analyses were calculated to 
examine any significant differences in prevalence rates between the FXS group and the 
non-syndromic ASD group for a DSM-5 diagnosis of ADHD as well as for symptom 
count criteria for each of the three sub-types of ADHD. In addition to answering the 
previous research questions, a number of descriptive statistics are included for review to 
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help further characterize and understand the behavioral makeup of adolescents and adults 
with FXS and ASD in the present sample due to the lack of knowledge that is present in 
the current literature for these clinical groups. This includes looking at medication 
treatments in both of this study’s samples to help understand the impact of medication on 
the rating and presentation of symptoms at this age. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  21 
 
 
 
CHAPTER 3 
RESULTS 
3.1 PREVALENCE OF ADHD IN FXS 
To analyze our first research question, prevalence rates for each of the ADHD 
subtypes were obtained for the FXS group. For ADHD-I 29% of individuals met criteria 
(n = 9); for ADHD-H 6.5% (n = 2); and for ADHD-C 12% (n = 4). Thus, 48.3% of the 
FXS sample met diagnostic criteria for ADHD as defined by the DSM-5 (n = 15).  
3.2 AUTISM SYMPTOM SEVERITY AS A PREDICTOR OF ADHD IN 
ADOLSCENT AND ADULT MALES WITH FXS 
 To analyze our second research question, a logistic regression model was run to 
determine if autism symptom severity was predictive of a diagnosis of ADHD in the FXS 
sample. No significant results were found F(1,1) = -.098, p = .545.  
3.3 DIFFERENCES BETWEEN RATES OF ADHD IN ADOLESCENTS AND 
ADULTS WITH FXS AND NON-SYNDROMIC ASD 
To analyze our third research, question chi-squared tests were run. No significant 
differences were found between the FXS and ASD groups for any of the ADHD 
subtypes; ADHD-I: X2 (1) = 1.375, p = .244; ADHD-H: X2 (1) = .212, p = .645; ADHD-
C: X2 (1) = .099, p = .753; nor for a collective DSM-5 diagnosis of ADHD X2 (1) = .833, 
p = .361.  
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3.4 PREVALENCE OF ADHD IN NON-SYNDROMIC ASD 
Prevalence of ADHD in the ASD group was as follows: 40% met for ADHD-I (n 
= 8), 5% met for ADHD-H (n = 1), and 10% met for ADHD-C (n = 2).  
3.5 DIFFERENCES IN ADHD PREVALENCE BASED ON CLINICAL FACTORS 
In the present study 60% of the non-syndromic ASD sample were categorized as 
having ID (the remaining eight range from low average to above average IQ). Of these, 
66% yielded a diagnosis of ADHD. This rate is much higher than what has been found in 
previous ID research. In the FXS group 23 participants had FXS+ASD based on ADOS 
severity scores. Of these, 47.8% met for a diagnosis of ADHD. Similar rates were found 
in the FXS only group. See Table 3 for a summary of these findings. 
3.6 MEDICATION USE IN THE PRESENT SAMPLE 
We also descriptively looked at stimulant medication use in each of our samples. 
In the FXS group 48.3% of the sample indicated that they were receiving medication to 
target attention and/or hyperactivity. Of these 60% were taking a stimulant medication. In 
the ASD group only 15% of the sample indicated they were receiving medication to 
target attention and/or hyperactivity. All of these individuals were receiving stimulant 
medicants. One participant in this group was taking two stimulant medications.   
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Table 3.1 
 
Breakdown of ADHD subtype prevalence by clinical group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 n Any 
ADHD 
ADHD-I ADHD-H ADHD-
C 
 
Whole FXS 
Group 
31 45% 29% 5% 11%  
FXS+ASD 23 47.8% 21.7% 8.6% 17.4%  
FXS only 8 50% 50% 0 0  
Whole ASD 
Group 
20 55% 40% 5% 10%  
ASD+ID 12 75% 50% 8.3% 8.3%  
ASD w/o ID 8 62.5% 37.5% 12.5% 12.5%  
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CHAPTER 4 
DISCUSSION 
Attention Deficit/Hyperactivity Disorder is the most commonly diagnosed 
comorbid disorder within FXS, with rates ranging between 40% to 80% (Backes et al., 
2000; Lo-Castro, D&apos;Agati, & Curatolo, 2011; Reilly et al., 2015). In the general 
population symptoms of ADHD cause significant impairment in social functioning and 
peer relationships in childhood (De Boo & Prins, 2007; Erhardt & Hinshaw, 1994). 
Further, many of these symptoms last into adulthood and cause impairments that impact 
many facets of everyday living that can impede high quality and successful independent 
living in the general adult population. The symptoms of ADHD that are maintained in 
adults in the general population, are also maintained in populations of adults with 
developmental and genetic disorders. The present study investigated the presence of 
ADHD in FXS and if autism severity is a significant predictor of ADHD in FXS, using a 
homogenous genetic sample. The present study also directly compared ADHD in FXS to 
another neurodevelopmental disorder that is also highly associated with ADHD. 
4.1 FXS FINDINGS 
The overall prevalence of a diagnosis of ADHD in the present sample of adolescents and 
adults with FXS was 48.3%. This number falls in the lower range of rates that have been 
found in previous diagnostic samples for children with FXS (Backes et al., 2000; Sullivan 
et al., 2006), which ranges from 46% to 54%. These findings did not support our 
hypothesis which was that 75% of the FXS would meet for a diagnosis of ADHD. 
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However, there are two ways to interpret these findings. The current finding of 48.3% is 
consistent with what has been found in other studies indicating that the use of the 
PChIPS, as a diagnostic measure in FXS, is likely a valid measurement tool. 
However, with little research on the diagnostic rates that extend into the adult 
FXS population, more research needs to be conducted in order to discern whether or not 
diagnostic rates found in adolescence and childhood are indeed maintained into early 
adulthood. Second, the symptom count of six was used in order to meet for a diagnosis of 
ADHD in the present study. This decision was based on the mental age and general 
functioning of individuals with FXS. However, in exploratory, descriptive analyses, we 
looked at rates of ADHD when using the diagnostic cut-off of five symptoms, which the 
current DSM allows for individuals over the age of 12. When using the chronological 
cut-off for symptom criteria instead of the mental age cut-off, rates of ADHD diagnosis 
on the PChIPS tripled. These exploratory findings suggest that measurement criteria 
under the DSM-5 for ADHD need to be studied further in individuals with FXS and 
within other samples of individuals with ID when considering diagnoses for older 
individuals. These differences in rates could significantly impact how we view 
trajectories of ADHD over the life course in FXS as well as impact how and when we 
provide intervention to these individuals.  
4.2 PREDICTIVE MODEL RESULTS 
In a logistic regression model looking at the predictive ability of autism symptom 
severity on a diagnosis of ADHD within our FXS sample, no significance was found. 
These results are similar to those found in previous literature that examine a younger 
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 sample that includes both males and females (Newman et al., 2015). This finding does 
not support our hypothesis that individuals with FXS+ASD would show higher rates of 
ADHD than those with FXS only. However, when looking at a descriptive breakdown 
between the FXS+ASD and FXS only group, interesting differences are observed. When 
looking at diagnostic rate differences between these two groups, in the FXS only group, 
these individuals only met for a diagnosis of ADHD-I, whereas individuals in the 
FXS+ASD group met for diagnoses in all three categories. Thus, maybe the question is 
not about whether or not individuals meet for a diagnosis of ADHD but what type of 
diagnosis they meet for as this can also guide and information how we treat individuals 
who meet for different subtypes of ADHD. 
4.3 ASD FINDINGS 
Diagnostic rates of ADHD in individuals with non-syndromic ASD in the present 
study was 55%. This rate is in line with rates of ADHD in ASD found in previous 
literature (Goldstein and Schwebach, 2004, 59%; Ponde et al., 2010, 53%; Ghanizadeh 
2012, 54%; and Stevens, 2016, 54%). However, these listed studies utilized samples of 
children ranging in ages from six to 18 years old; thus, not tapping into the adult age 
population. This finding suggests that rates of ADHD in non-syndromic ASD found in 
childhood are maintained into adolescence and early adulthood. However, similar to rates 
within the FXS sample, when looking at diagnostic symptom criteria of five instead of 
six rates in the ASD sample also increased. 
4.4 DIFFERENCES BETWEEN FXS AND NON-SYNDROMIC ASD GROUP 
No significant differences were found between the diagnostic rates of each of the 
three subtypes of ADHD between the ASD and FXS groups. These findings did not 
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support our hypothesis that rates for ADHD would be higher in the FXS than in the ASD 
group. However, when considering the measurement questions related to deciding on 
which symptom count DSM-5 criteria to use with adolescents and adults with ID, calls 
into question the validity of these findings. Much more research is needed to help explain 
valid measurement criteria, and accurate rates of ADHD in clinical populations such as 
FXS and ASD. Regardless the high rates of diagnostic prevalence in comparison to what 
is found in the general population indicate not only that we are insufficiently mitigating 
these behaviors earlier in development, but that treatment and intervention are still 
needed for older individuals with a comorbid diagnosis of FXS and ADHD or ASD and 
ADHD. 
Further, these findings point to a shared phenotype of ADHD within the presence 
of FXS and non-syndromic ASD due to lack of significant differences found between 
these groups. These shared phenotypes could mean that interventions found successful 
for challenging behaviors in one of these clinical groups could also be successful in the 
other.  
4.5 SUMMARY 
Findings from the current study suggest that diagnostic prevalence rates in 
adolescents and young adults with FXS are lower than what has been found in childhood 
for this population. This could be due to several factors. It is likely that many parents are 
unable to recognize the behavioral characteristics of ADHD as uniquely different from 
the behaviors commonly found in FXS. It could also be that many of the behavioral 
challenges seen in individuals with FXS are not identified as impairing to some families; 
especially later in development when behaviors have stabilized, medication intervention 
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is working (Roberts et al., 2011) or families have had almost two decades to understand 
and adjust to behaviors. However, given the reduced rates of ADHD in adults versus 
children observed in the general community, it is not unanticipated that we observed 
lower rates in our samples. Despite the lower rates in these older aged individuals, the 
prevalence is still quite high and higher than community samples indicating the need for 
sustained treatment at these older ages. The fact that rates in the present study are not 
significantly lower than those found in childhood again highlights the need for more 
behavioral interventions earlier in development to help lower the symptoms and 
diagnostic rates seen in adolescence and adulthood. However, the higher rates found in 
the present study make sense as children who are more impaired tend to have a higher 
percentage of comorbid diagnoses and present with more severe phenotypic behaviors. 
4.6 LIMITATIONS 
The present study is not without limitations. The number of participants within 
each group was limited particularly in the ASD group. Future research should aim to 
increase sample sizes within these groups. Additionally, the use of parent report can be 
viewed as a limitation as parent perceptions of impairment can be skewed due to the 
significance and level of impairment in children with ID and particularly children with 
FXS. However, parent report is also a vital aspect of behavioral research and using parent 
report along with clinical judgement should be used together to help further disentangle 
the presence of ADHD from FXS specific behaviors. Although the PChIPS was validated 
in a sample of individuals with ASD it has not yet been studied in individuals with FXS. 
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4.7 IMPLICATIONS 
The present study has identified the diagnostic rates of ADHD in two adolescent 
and adult male neurodevelopmental disorders. The implications of diagnostic rates of 
ADHD at ~50% in adolescents and adults with FXS and ASD indicates an increased need 
for behavioral interventions at younger ages in these clinical populations. In literature 
looking at intervention effectiveness for ADHD in the general population, effectiveness 
for behavioral interventions for ADHD have high efficacy rates (Fabiano et al., 2009; 
Sonuga-Barke et al., 2013). These rates tend to increase when medication intervention is 
used in tandem with behavioral interventions (MTA Cooperative Group, 2004; Pelham 
Jr. et al., 2000). Although, it can be speculated that the same behavioral interventions 
used with individuals in the general population may not be effective for individuals with 
FXS or those with low functioning ASD due to low IQ. However, no behavioral 
intervention studies have been conducted with individuals with FXS with a comorbid 
diagnosis of ADHD, as current intervention tends to solely focus on the use of 
medication. Although medication use for the treatment of ADHD has been proven 
effective in individuals with FXS, future research should look at the utility of 
implementing behavioral interventions with individuals with FXS who show symptoms 
of ADHD, as stated that current evidenced-based literature shows that the combination of 
using medication to lessen the symptom presentation of ADHD in cohesion with 
behavioral interventions for ADHD symptoms could have significant impact on long-
term functioning and life time health care costs for this population. Since medications 
allow for individuals to access the benefits of intervention, setting individuals up to be 
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more successful in behavioral interventions, combining these two strategies and younger 
ages in individuals with FXS and ADHD could be critical.  
Additionally, this study shows the need for job and life support interventions to 
include ADHD in order for individuals attempting to obtain some levels of independence 
to be more successful in these endeavors. Not only will the combination of medication 
and intervention improve behavioral functioning for individuals with FXS and ADHD, it 
will also improve their social functioning which opens doors to access a variety of 
positive benefits in the future and increasing life skills functioning. Thus, future research 
should look at behavioral interventions that may be effective in helping to decrease the 
impact of ADHD behaviors in FXS with ASD. Future research should also focus on the 
early identification of comorbidities and symptom presence within FXS through both 
behavioral research and bio-behavioral methods. Through the utilization of bio-
behavioral methods such as eye-tracking and heart rate variability, earlier identification 
of children with impairing symptoms can be identified as well as appropriate treatment 
interventions. With earlier identification of these impairing behaviors with proven 
effective interventions we can aim to decrease the rates of ADHD and medication use 
that we see in these adolescent and adults with FXS syndrome and ultimately improve 
long-term outcomes and later in life functioning.  
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